Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors

Coronado Biosciences, Inc.

announced today the execution of an exclusive license agreement with NeuPharma, Inc. to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is currently in pre-clinical development. Under the terms of the agreement, Coronado will pay NeuPharma an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales. Dr. Lindsay A. Rosenwald, Chairman and CEO stated, "Targeting EGFR mutations with 3rd generation covalently-bound inhibitors has demonstrated clear activity in patients with Non-Small Cell Lung Cancer (NSCLC) carrying specific EGFR mutations while avoiding the toxicity seen with first and second generation inhibitors that also target wild type EGFR, which typically results in dose limiting side effects such as diarrhea and rash. We believe the inhibitors developed by NeuPharma may have distinct advantages even over the current 3rd generation compounds in this class. NeuPharma has a portfolio of these inhibitors, the most advanced of which could reach the clinic in the first half of 2016." Dr. Rosenwald continued, "We are very excited to add this novel program to our growing portfolio. Since restructuring the Company a little over a year ago, our goal has been to build a diverse portfolio of subsidiary companies and product opportunities, and we believe this program adds another important piece to the overall business plan." "We are very pleased to be collaborating with Coronado. This collaboration will greatly accelerate the global development and commercialization of our 3rd Generation EGFR inhibitors discovered using our structure-based drug design platform," stated Shawn Qian, Ph.D., President and CEO of NeuPharma